Literature DB >> 26226490

Novel Oxazolidinone-Based Peroxisome Proliferator Activated Receptor Agonists: Molecular Modeling, Synthesis, and Biological Evaluation.

N Fresno1, M Macías-González2,3, A Torres-Zaguirre1, M Romero-Cuevas2,3, P Sanz-Camacho1, J Elguero1, F J Pavón2,3, F Rodríguez de Fonseca2,3, P Goya1, R Pérez-Fernández1,4.   

Abstract

A series of new peroxisome proliferator activated receptors (PPARs) chiral ligands have been designed following the accepted three-module structure comprising a polar head, linker, and hydrophobic tail. The majority of the ligands incorporate the oxazolidinone moiety as a novel polar head, and the nature of the hydrophobic tail has also been varied. Docking studies using the crystal structure of an agonist bound to the ligand binding domain of the PPARα receptor have been performed as a tool for their design. Suitable synthetic procedures have been developed, and compounds with different stereochemistries have been prepared. Evaluation of basal and ligand-induced activity proved that several compounds showed agonist activity at the PPARα receptor, thus validating the oxazolidinone template for PPAR activity. In addition, two compounds, 2 and 4, showed dual PPARα/PPARγ agonism and interesting food intake reduction in rats.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26226490     DOI: 10.1021/acs.jmedchem.5b00849

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  1 in total

1.  Computational identification of potential chemoprophylactic agents according to dynamic behavior of peroxisome proliferator-activated receptor gamma.

Authors:  Zhiwei Yang; Yizhen Zhao; Dongxiao Hao; He Wang; Shengqing Li; Lintao Jia; Xiaohui Yuan; Lei Zhang; Lingjie Meng; Shengli Zhang
Journal:  RSC Adv       Date:  2020-12-22       Impact factor: 3.361

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.